Back to Search
Start Over
Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors.
- Source :
-
The Annals of pharmacotherapy [Ann Pharmacother] 2006 Oct; Vol. 40 (10), pp. 1731-6. Date of Electronic Publication: 2006 Sep 12. - Publication Year :
- 2006
-
Abstract
- Background: Pharmacokinetic studies have shown that the concomitant use of atazanavir and proton pump inhibitors (PPIs) decreases atazanavir plasma concentrations. Data describing clinical outcomes associated with this drug interaction are limited.<br />Objective: To describe the clinical outcomes, in terms of viral load (VL) suppression, associated with the concurrent use of ritonavir-boosted or unboosted atazanavir and PPIs.<br />Methods: A retrospective chart review of 301 HIV-positive adults attending an Ohio infectious diseases clinic was performed to identify patients prescribed atazanavir, with or without ritonavir, and a PPI. The primary outcome was achievement/maintenance of VL less than 400 copies/mL for 2 or more months during concomitant atazanavir and PPI therapies. Data collected included VL and CD4+ cell count at initiation of coadministered atazanavir and PPIs, genotype/phenotype, prior protease inhibitor experience, length of concurrent atazanavir/PPI therapy, and adherence.<br />Results: Twelve patients met inclusion criteria. PPIs and dosing regimens varied among subjects. Five of the subjects had a VL less than 400 copies/mL at initiation of atazanavir, with or without ritonavir, which was maintained during concurrent atazanavir and PPI therapy. Four additional subjects initiated protease inhibitor treatment with a VL greater than 400 copies/mL and achieved an undetectable VL while on concurrent PPI therapy. Duration of concurrent therapy ranged from 4 to 23 months in these 9 subjects. Of the 3 patients not maintaining a VL less than 400 copies/mL, 1 achieved that level at 4 months, and all 3 of these subjects showed atazanavir susceptibility during therapy per genotype resistance testing. Subsequently, decreased atazanavir susceptibility was reported in 1 of the 3 patients after 18 months of therapy. Patients not achieving an undetectable VL had known adherence issues.<br />Conclusions: In this case series, 9 of 12 subjects achieved successful virologic outcomes while receiving concurrent atazanavir and PPIs in a real-world environment. In our experience, the interaction between atazanavir and once-daily PPIs is not clinically significant for adherent patients. Concurrent use of these medications could be considered in patients with limited treatment options.
- Subjects :
- Adult
Atazanavir Sulfate
Drug Interactions
Drug Therapy, Combination
Female
HIV Infections blood
HIV Infections drug therapy
HIV-1
Humans
Male
Middle Aged
Oligopeptides blood
Proton Pumps blood
Pyridines blood
Retrospective Studies
Treatment Outcome
Oligopeptides administration & dosage
Proton Pump Inhibitors
Pyridines administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1542-6270
- Volume :
- 40
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- The Annals of pharmacotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 16968825
- Full Text :
- https://doi.org/10.1345/aph.1H217